Clinical Trials Directory

Trials / Completed

CompletedNCT03095508

Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat

Prospective, Multicenter, Open, Randomized, Parallel, Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray [Menthol], 0,5 mg + 2 mg / 1 ml (Sandoz d.d., Slovenia), and ANTI-ANGIN® FORMULA, Topical Metered Spray, 0,12 mg + 0,24 mg / Dose (OOO "Valeant", Russia) in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
229 (actual)
Sponsor
Sandoz · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to evaluate no less therapeutic efficacy and safety of the Angal S, topical spray \[Menthol\], 0,5 mg + 2 mg (Sandoz dd, Slovenia) compared to ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC "Valeant", Russia) in treatment of patients with uncomplicated acute infectious and inflammatory diseases of the pharynx, accompanied by a sore throat.

Conditions

Interventions

TypeNameDescription
DRUGAngal S, topical spray [Menthol]0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
DRUGANTI-ANGIN® FORMULA, topical metered spray0,12 mg + 0,24 mg (LLC "Valeant", Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution

Timeline

Start date
2017-02-22
Primary completion
2017-05-08
Completion
2017-05-08
First posted
2017-03-29
Last updated
2019-03-21
Results posted
2019-03-21

Locations

14 sites across 1 country: Russia

Source: ClinicalTrials.gov record NCT03095508. Inclusion in this directory is not an endorsement.